MELLERIL |
MELLARIL |
RIDERIL |
TP-21 |
MELLARIL-S |
THIORIDAZINE |
THIORIDAZIN |
MEL269 |
TIORIDAZINA |
THIORIDAZINUM |
3-METHYLMERCAPTO-N-(2'-(N-METHYL-2-PIPERIDYL)ETHYL)PHENOTHIAZINE |
MELLARIL® |
10-[2-(1-METHYL-2-PIPERIDYL)ETHYL]-2-METHYLSULFANYL-PHENOTHIAZINE |
2-METHYLMERCAPTO-10-(2-(N-METHYL-2-PIPERIDYL)ETHYL)PHENOTHIAZINE |
chemidplus:50-52-2 |
chembl:CHEMBL479 |
drugbank:00679 |
rxcui:10502 |
pubchem.compound:5452 |
Drug Class | antipsychotic agents |
Year of Approval | 1962 |
FDA Approval | 1962 |
Drug Class | small molecule |
Drug Indications | Antipsychotic Agents |
Drug Categories | psycholeptics |
Drug Groups | withdrawn |
Drug Categories | adrenergic alpha-1 receptor antagonists |
Drug Categories | adrenergic alpha-antagonists |
Drug Categories | adrenergic antagonists |
Drug Categories | agents that produce hypertension |
Drug Categories | antidepressive agents |
Drug Categories | cytochrome p-450 cyp2e1 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | dopamine d2 receptor antagonists |
Drug Categories | drugs causing inadvertant photosensitivity |
Drug Categories | heterocyclic compounds, fused-ring |
Drug Categories | neurotoxic agents |
Drug Categories | photosensitizing agents |
Drug Categories | qtc prolonging agents |
Drug Categories | serotonergic drugs shown to increase risk of serotonin syndrome |
Drug Categories | serotonin 5-ht2 receptor antagonists |
Drug Categories | serotonin agents |
Drug Categories | serotonin receptor antagonists |
antagonist (inhibitory) |
Direct Interaction? | True |
Endogenous Drug? | False |
Specific Action of the Ligand | Antagonist |
antagonist (inhibitory) |
Trial Name | - |
Novel drug target | Established target |
Mechanism of Interaction | D2-like dopamine receptor antagonist |
antagonist (inhibitory) |
Novel drug target | Established target |
Trial Name | - |
Endogenous Drug? | False |
antagonist (inhibitory) |
Trial Name | - |
Novel drug target | Established target |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
antagonist (inhibitory) |
Endogenous Drug? | False |
Specific Action of the Ligand | Inverse agonist |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
Direct Interaction? | True |
antagonist (inhibitory) |
Specific Action of the Ligand | Inverse agonist |
Endogenous Drug? | False |
antagonist (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | D2-like dopamine receptor antagonist |
antagonist (inhibitory) |
Mechanism of Interaction | D2-like dopamine receptor antagonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Endogenous Drug? | False |
Specific Action of the Ligand | Antagonist |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
THIORIDAZINE | DrugBank Drug Name |
50-52-2 | CAS Number |
Aldazine | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | withdrawn |
THIORIDAZINE | Primary Drug Name |
Year of Approval | 1962 |
Drug Class | antipsychotic agents |
Drug Indications | Antipsychotic Agents |
Drug Class | small molecule |
FDA Approval | 1962 |
CHEMBL479 | ChEMBL Drug ID |
D0U1OE | TTD Drug ID |
THIORIDAZINE | GuideToPharmacology Ligand Name |